Canakinumab Versus Placebo in Combination With First-Line Pembrolizumab Plus Chemotherapy for Advanced Non–Small-Cell Lung Cancer: Results From the CANOPY-1 Trial - Concepedia

Concepedia

Publication | Closed Access

Canakinumab Versus Placebo in Combination With First-Line Pembrolizumab Plus Chemotherapy for Advanced Non–Small-Cell Lung Cancer: Results From the CANOPY-1 Trial

62

Citations

22

References

2023

Year

Daniel S.W. Tan, Enriqueta Felip, Gilberto de Castro, Benjamin Solomon, Alastair Greystoke, Byoung Chul Cho, Manuel Cobo, Tae Min Kim, Sandip Ganguly, Enric Carcereny,

Journal of Clinical Oncology

Abstract

The addition of canakinumab to first-line pembrolizumab and CT did not prolong PFS or OS in patients with NSCLC.

References

	Year	Citations

Page 1